Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

The Sultanate of Oman is the third country worldwide to implement this project, confirming its commitment to technological ...

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an increased risk of rare eye conditions.

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

More evidence shows a risk between GLP-1 drugs and vision risks. A study in JAMA Network Open adds more evidence linking ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

A new study by researchers at Unity Health, Sunnybrook Health Sciences Center and the University of Toronto has found that ...

Diabetic retinopathy and diabetic macular edema (DME) are two of the most common vision conditions related to diabetes. They affect about 1 in 4 people with type 1 and type 2 diabetes.

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.